IN8bio (INAB) Competitors $2.10 -0.08 (-3.67%) Closing price 04:00 PM EasternExtended Trading$2.19 +0.09 (+4.29%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. TPST, CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, and SNYRShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics FibroBiologics Klotho Neurosciences NanoViricides BioAtla Synergy CHC IN8bio (NASDAQ:INAB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is INAB or TPST more profitable? IN8bio's return on equity of -218.85% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -218.85% -139.59% Tempest Therapeutics N/A -305.51%-119.74% Do analysts prefer INAB or TPST? IN8bio presently has a consensus price target of $180.00, indicating a potential upside of 8,471.43%. Tempest Therapeutics has a consensus price target of $30.00, indicating a potential upside of 323.73%. Given IN8bio's stronger consensus rating and higher possible upside, research analysts plainly believe IN8bio is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor INAB or TPST? In the previous week, Tempest Therapeutics had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for IN8bio. Tempest Therapeutics' average media sentiment score of 0.41 beat IN8bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment IN8bio Neutral Tempest Therapeutics Neutral Do institutionals and insiders believe in INAB or TPST? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, INAB or TPST? Tempest Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.44M-$13.57-0.15Tempest TherapeuticsN/AN/A-$41.84M-$17.98-0.39 SummaryIN8bio beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.60M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.157.5519.3119.89Price / SalesN/A284.29424.59117.07Price / CashN/A41.7026.2128.59Price / Book0.357.397.925.55Net Income-$30.44M-$55.04M$3.17B$248.49M7 Day Performance0.48%3.01%2.18%5.37%1 Month Performance-49.64%-0.21%1.25%6.63%1 Year Performance-91.25%4.48%33.90%21.20% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio2.2931 of 5 stars$2.10-3.7%$180.00+8,471.4%-90.7%$6.60MN/A-0.1520TPSTTempest Therapeutics1.6221 of 5 stars$6.80-1.4%$30.00+341.2%-72.8%$25.41MN/A-0.3820CARACara Therapeutics0.3381 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2486 of 5 stars$5.76-1.5%$17.50+203.8%+88.0%$24.27MN/A-2.329LSTALisata Therapeutics2.4741 of 5 stars$2.90+3.6%$15.00+417.2%-24.8%$24.12M$1M-1.2630Positive NewsCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.522 of 5 stars$0.62+0.7%$13.00+1,989.4%-87.0%$23.65MN/A0.0010News CoverageGap UpKLTOKlotho NeurosciencesN/A$1.13+56.9%N/AN/A$23.40MN/A0.00N/AAnalyst UpgradeGap DownHigh Trading VolumeNNVCNanoViricides1.0921 of 5 stars$1.40flatN/A-20.0%$22.50MN/A-1.9420News CoveragePositive NewsBCABBioAtla2.715 of 5 stars$0.40+3.1%$5.00+1,162.6%-71.2%$22.43M$11M-0.3260SNYRSynergy CHC3.5869 of 5 stars$2.85+17.3%$10.00+250.9%N/A$22.34M$34.83M0.0040Gap UpHigh Trading Volume Related Companies and Tools Related Companies TPST Competitors CARA Competitors TENX Competitors LSTA Competitors CYTH Competitors FBLG Competitors KLTO Competitors NNVC Competitors BCAB Competitors SNYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
